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Abstract
A proof-of-concept aptamer-based optical assay is described for the determination of the immuno signalling molecule
interleukin-6 (IL-6), a key marker of acute inflammation. The optical assay is based on the aggregation of gold
nanoparticles (AuNP) coated in two complimentary “sandwich-style” aptamers, each with different IL-6 target moieties.
IL-6 will recognise the complimentary aptamer pair and bind to it, thereby causing the aggregation of the corresponding
functionalised nanoparticles. The aggregation of the AuNPs after exposure to IL-6 induces a visible colour change from
red to pink, with a corresponding change in the absorption maximum from 520 to 540 nm. The change in the absorption
maximum can be monitored visually, or by using a spectrophotometer or a plate reader. The optimal size and function-
alisation of aptamer-coated AuNPs, and the potential assay formats were investigated using UV-vis spectrophotometry,
transmission electron microscopy, and dynamic light scattering. The optical assay was applied for detecting mouse IL-6
in a mixed protein solution as a representative biological sample. The assay works in the 3.3 to 125 μg·mL−1 IL-6
concentration range, and the detection limit (at S/N = 3) is 1.95 μg·mL−1. This study was performed as a proof-of-
concept demonstration of this versatile assay design, with a view to developing a similar assay for use in clinical
samples in future.
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Introduction
Inflammation, the body’s immune response to infection or
injury, plays a key role in almost all pathological conditions.
Inflammation is mediated by immune molecules which act as
chemical messengers yielding a response from other cells.
Different types of immune molecules have been associated
with driving inflammation, or a redirection to a healing func-
tion. There is increasing evidence that early detection of in-
flammatory molecules can enable timely clinical intervention
with potentially life-saving consequences for patients. This is
particularly true for pathological conditions in hidden environ-
ments such as the brain, where changes in inflammatory pro-
cesses are not always immediately obvious from a clinical
perspective.
Interleukin-6 (IL-6) is an immunemolecule associated with
acute inflammation, particularly in response to recent infec-
tion or injury [1]. High levels of IL-6 measured in cerebrospi-
nal fluid (CSF) and plasma have been associated with patho-
logical inflammation leading to poor clinical outcome in pa-
tients with brain injuries, such as traumatic brain injury (TBI)
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[2, 3] and subarachnoid haemorrhage (SAH) [4, 5]. IL-6
above a certain threshold in CSF drain samples has been
recognised as a potentially important diagnostic marker of
bacterial meningitis [6]. Bedside detection of raised IL-6
would potentially enable rapid treatment of meningitis with
anti-inflammatory steroids, thereby decreasing the risk of
mortality [6, 7]. IL-6 can also be used as an early indicator
of potentially life-threatening infection. Sepsis, which is sys-
temic, uncontrolled inflammation caused by the body’s reac-
tion to infection, is one of the most common causes of deaths
in a hospital environment, and is especially common in the
elderly [8]. Conventional diagnosis of sepsis relies on recog-
nition of infection, which can be challenging in comatose
patients. Positive microbiological cultures (which can take
days) remains the gold standard for diagnosis, along with
key clinical assessments including temperature, white cell
count (WCC), C-reactive protein (CRP), and blood lactate
[9, 10]. Significant developments in the field of sepsis diag-
nosis attempt to address the lengthy time required to perform
blood cultures. These include new real-time PCR, multiplex
PCR-based assays, and microarray techniques for pathogen
identification directly from blood. Although these new
methods enable more rapid diagnosis, current limitations in-
clude high cost (£140–£160/test) and specialised laboratory
equipment requirements [11]. Bedside detection of raised IL-
6 levels in the blood would aid the diagnosis of infection,
thereby enabling the fast and effective treatment necessary to
combat this disease [8, 10, 12].
The growing trend for transition of diagnostic tests from
the laboratory to the point-of-care reflects the mounting evi-
dence that early detection of changes in the body enable rapid
clinical intervention with maximum benefit. This is particular-
ly relevant in cases of increased inflammation. Current com-
mercially available technology employs antibodies as detec-
tion agents, in both the clinical laboratory, and in point-of-care
diagnostics. An example is a bedside interleukin-6 test for the
early detection of infection in expectant mothers, to prevent
pre-term births [13]. This test uses antibodies to bind IL-6 and
enable detection. Antibodies are used as the recognition unit
in the majority of methods reported in the literature that could
be potentially apply for the detection of IL-6 in clinical diag-
nosis (Table S1). Antibodies are mass-produced in animals,
hybridoma cell ines or genetically-modified bacteria, with the
inherent risk of inter-batch variability; they require refrigerat-
ed storage and specific conditions for optimal performance,
and they can degrade with time, giving them limited shelf-life.
These disadvantages can limit the practicality of antibody-
based tests, and seeking alternatives to antibodies is therefore
of tremendous importance. Active research in this area has led
to the development of an automated system for the synthetic
production of aptamers, short DNA strands. Aptamers are
tuneable and enable high-affinity binding, resulting in im-
proved assay sensitivity [14, 15]. Crucially, their synthetic
method of production means that they are cheaper to produce,
and chemically identical than antibodies. Aptamers are also
more stable than antibodies and can be stored for long periods
without refrigeration [16]. The use of aptamers in place of
antibodies can potentially improve test sensitivity over current
state-of-the-art bedside tests, and enable smaller sample vol-
umes to be analysed.
The physical properties of gold nanoparticles (AuNP)
cause them to be brightly coloured in solution, and this colour
visibly changes in response to AuNP aggregation. Diagnostic
tests based on the aggregation of AuNP have been demon-
strated as highly effective for the detection of toxins, bacteria,
viruses (in allantoic fluid), and immune molecules in human
biological samples [17–19]. Tests of this nature offer signifi-
cant advantages over the current state-of-the-art in terms of
sensitivity, reliability, cost, and easy storage without refriger-
ation. They are particularly practical in a bedside setting as
they can be performed quickly and easily (in 20 min or less) at
room temperature and without sample pre-treatment [20].
AuNPs functionalised with heparin have been recently report-
ed for enhanced microdialysis sampling of cytokines [21].
In the present study, we report the development and pre-
liminary trial of a proof-of-concept version of a novel bedside
test for the detection of IL-6 in biological samples from pa-
tients with brain injury or infection. The test is based on AuNP
functionalised with a ‘sandwich-pair’ of aptamers specific for
murine IL-6. To the best of our knowledge, this is the first time
that a ‘sandwich-pair’ of aptamers is reported for the optical
detection of IL-6 using gold nanoparticles. The presence of
IL-6, which binds to multiple aptamers on the AuNP surface,
results in aggregation of the AuNP as schematically shown in
Fig. 1. In this pilot study, the optical assay was applied for the
detection of mouse IL-6 in a mixed protein solution as a rep-
resentative biological sample matrix as an initial proof-of-con-
cept. With further development, the new technique may be
applicable for the rapid and straightforward detection of acute
inflammation in either a mouse model, or in mouse-derived
cell culture supernatant. The test is performed without previ-
ous sample treatment and requires only 5 min to complete,
making it useful in a wide range of clinical settings. The assay
design is versatile. In future, it may be adapted to a ‘dip-stick’
format.
Experimental
Materials and equipment
High-purity deionised water (dH2O) used was of HPLC-grade
(18.2 MΩ·cm, Millipore Direct Q5 UVwater purification sys-
tem with LC-Pak polisher, https://www.merckmillipore.com).
All reagents were of analytical grade, purchased from Sigma-
Aldrich (Poole, Dorset, UK, https://www.sigmaaldrich.com)
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and used as received unless otherwise stated. Millipore
Millex-HV PVDF syringe filter units (0.45 μm) and
Millipore Amicon Ultra 0.5 mL centrifuge units (100 k
MWCO) were also purchased from Sigma-Aldrich (Poole,
Dorset, UK, https://www.sigmaaldrich.com). Sodium
phosphate dibasic, sodium chloride, sodium dodecyl sulfate
(SDS), and potassium chloride were purchased from BDH
Laboratory Supplies (Poole, UK, https://www.coleparmer.co.
uk). 1.5 mL and 5 mL Lo-bind Eppendorf tubes were pur-
chased from Thermo Fisher (Loughborough, UK, https://
www.thermofisher.com). Recombinant murine IL-6 standard
was purchased from PeproTech (London, UK, https://www.
peprotech.com). Complementary sandwich pair anti-murine
IL-6 aptamers (ATW0082 and ATW0077, with terminal
thiol-modification) and buffers (resuspension buffer and
aptamer reducing buffer) were purchased from BasePair
Biotechnologies Inc. (Pearland, Texas, USA, https://www.
basepairbio.com). Holey carbon film 300 mesh copper grids
were purchased from Agar Scientific (Stansted, UK, http://
www.agarscientific.com). ProcartaPlex human cytokine and
chemokine standard mixes A and B, and Universal Assay
Buffer were purchased from Affymetrix eBioscience
(Hatfield, UK, https://www.thermofisher.com).
All centrifugation steps were performed using a Hettich
320R centrifuge. Gentle agitation was achieved using a
Grant-Bio PS-3D Sunflower mini-shaker. Citrate AuNP
(cAuNP) synthesis was performed using a VWR hotplate
magnetic stirrer with temperature probe. UV-Vis absorption
spectra (200–800 nm) were recorded on a Hitachi U-3000
spectrophotometer at room temperature. Quartz cuvettes with
a 1 cm path length were used. Transmission electron micro-
scope (TEM) images were obtained using a FEI Tecnai F20
FEGTEM operating at 200 kV. Dynamic light scattering
(DLS) measurements of the 15 nm cAuNP were performed
on a Malvern Zetasizer Nano ZSP (running on Zetasizer 7.12
software). Measurement time, attenuation factor and detector
position were set as automatic. All other DLS measurements
were performed using a Wyatt Technologies DynoPro (DLS)
Plate Reader II with Corning 96-well plastic-bottom plates
(provided by Wyatt Technologies).
Gold nanoparticle (AuNP) synthesis
and characterisation
Citrate-stabilised gold nanoparticles (cAuNP) of ca. 15 nm
were synthesised according to the method of Turkevich et al.
[22]. Experimental details are given in the Electronic
Supporting Material.
Synthesis of ca. 50 nm cAuNP was performed using the
seeded growth method (for AuNPs of up to 180 nm) of Bastús
et al. [23]. Experimental details are given in the Electronic
Supporting Material.
Preparation of aptamer-functionalised AuNP
15 and 50 nm cAuNP were functionalised with thiolated
aptamers using the pH-assisted and surfactant-free method
previously reported by Zhang et al. [24, 25]. The thiolated
aptamers were first resuspended, folded, and reduced in ac-
cordance with the manufacturers’ instructions. Briefly, the
lyophilised aptamers (as received from the manufacturer)
were each reconstituted in ‘resuspension buffer’ to 100 μM.
The aptamers were diluted to 1:2 (50 μM) in phosphate-
buffered saline (PBS) (10 mM phosphate buffer, 2.7 mM po-
tassium chloride, 137 mM sodium chloride, pH 7.4; with
1 mM MgCl2). Folding was performed by heating the
aptamers to 95 °C for 5 min, before cooling slowly at room
temperature for 15 min. A 1:1 volume ratio of ‘aptamer
Fig. 1 A schematic of the
aptamer-gold nanoparticle-based
aggregation assay for the
detection of mouse IL-6
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reducing buffer’was added to each aptamer solution, followed
by a 10 min incubation at room temperature. The aptamers
were then diluted to a working concentration (either 22 or
28 μM) in trisodium citrate (10 mM, pH 3.0) for addition to
the cAuNP.
Aptamer-functionalised ca. 15 nm AuNP were prepared by
adding the aptamers (31.5 μL of a 22 μM solution, prepared
as described previously) to an aliquot of 15 nm cAuNP
(1.5 mL) in a 1.5 mL Eppendorf tube. For AuNP
functionalised with both aptamers on the same particle, the
stock solutions of each aptamer (prepared as described above)
were mixed (using a 1:1 ratio) prior to addition to the cAuNP.
After addition of the aptamers, the solution was then pipette-
mixed and left standing for 1 min at room temperature.
Trisodium citrate (30 μL of a 500 μM solution, pH 3.0) was
added to the AuNP and pipette-mixed, followed by a 10 min
incubation at room temperature. NaCl (52.5 μL of a 2 M so-
lution) was then slowly added (drop-wise). The solution was
then mixed by pipette and incubated for 20 min on a 3D
shaker (60 rpm) at room temperature. The solution, red in
colour, was treated with more NaCl (150μL of a 2M solution,
added dropwise). The solution was thenmixed by pipette once
again, and incubated for 40 min on a 3D shaker (60 rpm) at
room temperature. The aptamer-AuNP were then washed
three times to remove any unconjugated aptamers. The solu-
tion was centrifuged at 8000 rpm for 30 min in 100 k MWCO
ultrafiltration tubes. After the first centrifugation step, the
aptamer-AuNP were resuspended in 1.5 mL PB (10 mM,
pH 7.4) with 0.05% w/v tween-20. After the remaining centri-
fugation steps (and for storage), the aptamer-AuNP were re-
suspended in 1.5 mL PBS (10 mM phosphate buffer, 2.7 mM
potassium chloride, 137 mM sodium chloride, pH 7.4, 1 mM
MgCl2).Modification of the AuNP surface was determined by
UV-Vis spectrophotometry at ca. 520 nm. The ca. 15 nm
aptamer-AuNP were then stored at 4 °C before use.
Aptamer-functionalised ca. 50 nm AuNP were prepared by
adding the aptamers (180 μL of a 28 μM solution, prepared as
described previously) to an aliquot of 50 nm cAuNP (2mL) in
a 5 mL Lo-bind Eppendorf tube. For AuNP functionalised
with both aptamers on the same particle, the stock solutions
of each aptamer (prepared as described above) were mixed
(using a 1:1 ratio) prior to addition to the cAuNP. After addi-
tion of the aptamers, the solution was then pipette-mixed and
left standing for 1 min at room temperature. Trisodium citrate
(100 μL of a 500 μM solution, pH 3.0) was added to the
AuNP and pipette-mixed, followed by a 10 min incubation
at room temperature. NaCl (70 μL of a 2 M solution) was then
slowly added (drop-wise). The solution was then mixed by
pipette and incubated for 20 min on a 3D shaker (60 rpm) at
room temperature. The solution, red in colour, was treated
with more NaCl (200 μL of a 2 M solution, added drop-wise).
The solution was then mixed by pipette once again, and incu-
bated for 40 min on a 3D shaker (60 rpm) at room
temperature. The aptamer-AuNP were then washed three
times to remove any unconjugated aptamers. The solution
was then aliquoted into two 2 mL Eppendorf tubes, and cen-
trifuged at 4000 rpm for 15 min to form a pellet. After the first
centrifugation step, the aptamer-AuNP were resuspended in
2 mL PB (10 mM, pH 7.4) with 0.05% w/v Tween-20. After
the remaining centrifugation steps (and for storage), the
aptamer-AuNP were resuspended in 2 mL 1X PBS buffer
(pH 7.4, 1 mM MgCl2). Modification of the AuNP surface
was determined by UV-Vis spectrophotometry at ca. 540 nm.
The ca. 50 nm aptamer-AuNP were then stored at 4 °C before
use.
IL-6 aggregation assays and characterisation
by dynamic light scattering (DLS)
Aggregation assays were performed by adding increasing
concentrations of IL-6 (step-wise, from 0 to ≤125 μg·mL−1)
into a sample of aptamer-AuNP (300 μL) in a cuvette. For
single-aptamer-AuNP, equal volumes of aptamer-AuNP 1 and
aptamer-AuNP 2 were first combined in a cuvette and mixed
prior to IL-6 titration. For mixed-aptamer-AuNP the solution
was used as prepared. A UV-Vis spectrum was measured be-
fore the addition of the IL-6, and 5 min after each subsequent
addition. The 5 min incubation prior to eachmeasurement was
performed by capping the cuvette and placing it on a 3D
shaker (60 rpm) at room temperature. In order to control for
the dilution effect, a buffer control was performed alongside
the IL-6 test, in which equal volumes of the diluent (without
IL-6) were added prior to measurement.
Once the assay had been successfully applied for the mea-
surement of IL-6 in buffer, the aggregation assays were repeat-
ed on IL-6 in a representative biological matrix. All conditions
of the experiments were performed using the same protocol as
for the titration of IL-6 in buffer (as specified above), includ-
ing the 5 min incubation period at room temperature with light
agitation prior to measuring. This matrix comprised of a
mixed protein solution containing 0.5 mg·mL−1 human serum
albumin (HSA) and 34 human cytokines a chemokines, was
prepared as follows. The ProcartaPlex mixed human cytokine/
chemokine standards (A and B), received as lyophilised pow-
ders, were resuspended in accordance with the manufacturers’
instructions. Subsequently, the standards were diluted to 1:100
in ProcartaPlex Universal Assay Buffer with 0.5 mg·mL−1
HSA. The cytokine and chemokine concentrations of this ma-
trix solution are as shown in the Electronic Supporting
Material (Table S2). For the test, murine IL-6 standard (as a
1 mg·mL−1 stock solution in dH2O) was added to the matrix
prior to titration. For the negative control, an equal volume of
dH2O (without murine IL-6) was added to the matrix solution
prior to testing. A buffer control, consisting of ProcartaPlex
Universal Assay Buffer with 0.5 mg·mL−1 HSA (without
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additional proteins), was also tested to check for cross-
reactivity with the human proteins.
Upon completion of the aggregation assays, aptamer-
AuNP and aggregation assay particle size estimations were
performed by DLS using a DynoPro (DLS) Plate Reader II
(as previously described).
Results and discussion
AuNP synthesis and characterisation
Citrate-capped gold nanoparticles (cAuNPs) were synthesised
according to the citrate reduction methods of Turkevich et al.
(ca. 15 nm) and Bastús et al. (ca. 50 nm), as described in the
Electronic Supporting Material [22, 23]. The average diame-
ters of the cAuNP, measured from TEM images, are 15.0 ±
1.3 nm and 53.0 ± 5.2 nm (n = 100) (Fig. S1).
The cAuNP were functionalised with thiolated aptamers via
the pH-assisted method of Zhang et al. as described in the
Electronic Supporting Material [24, 25]. The binding of the
aptamers to the surface of the AuNP is demonstrated by a shift
in the absorption wavelength of approximately 3–4 nm follow-
ing functionalisation. The UV-Vis absorption spectra that sup-
port this statement are shown in Fig. S1c and f for 15 nm and
50 nm AuNPs, respectively. This shift to the red region of the
spectrum is indicative of modification of the surface of the
AuNP, resulting in a size increase which is reflected by in-
creased absorption wavelength. The increase in particle size
following addition of aptamers to the AuNP surface was also
determined by DLS, yielding an average size increase (post-
functionalisation) of 38.8 ± 5.1 nm (see Table S3 for complete
DLS results). These results combined confirm the successful
addition of aptamers to the particle surface.
Aggregation assay - preliminary development
Twomain aspects of the aggregation assay thought to improve
assay performance are investigated during this study: i) the
size of the AuNP core, and ii) the arrangement of the aptamers
on the AuNP surface. The effect of AuNP core size on aggre-
gation is initially investigated, in line with the findings of
Krpetić et al. who showed that larger AuNP elicited an im-
proved response in aggregation-based assays [26]. Here two
sizes of AuNP are trialled; smaller ca. 15 nmAuNP, and larger
ca. 50 nm AuNP. The aptamer-AuNP used for these experi-
ments are functionalised in a single (rather than mixed) ar-
rangement, yielding two AuNP solutions - AuNP-aptamer 1
and AuNP-aptamer 2. Equal volumes of the two
functionalised AuNP solutions are then combined and mixed
in a quartz cuvette (using a 1:1 ratio) prior to IL-6 addition and
measurement (as detailed in the Methods section). Increasing
volumes of IL-6 standard diluted in PBS, (10 mM phosphate
buffer, 2.7 mM potassium chloride, 137 mM sodium chloride,
pH 7.4) are then titrated into the solutions of aptamer-AuNP.
After a 5 min incubation at room temperature, the test is com-
plete and a UV-Vis absorption spectrum is taken after each
addition of IL-6. Aggregation of the AuNP in the presence of
IL-6 is indicated by a decrease in absorption intensity and a
shift in the maximum wavelength.
Examples of decreasing peak absorption (of the aptamer-
AuNP) in response to increasing concentrations of IL-6 from
these initial tests are shown in Fig. 2a and c (for 15 and 50 nm
aptamer-AuNP, respectively). It is hypothesised that, by using
AuNP with a larger core size, the response to IL-6 in the μg·
mL−1 range would be improved. The results show that for the
smaller AuNP core-size (Fig. 2b), the response is not readily
distinguishable from the control (in which equal volumes of
buffer were added instead of IL-6). A shift in the wavelength
maximum occurs in response to the addition of IL-6 (indicat-
ing enlarging of the particles, and therefore suggesting aggre-
gation). For example, for the 15 nm AuNP core size, this shift
is 4 nm after addition of IL-6 to 56.6 μg·mL−1 (compared to a
1.0 nm shift for the buffer control) in the experiment shown in
Fig. 2. For the larger AuNP size, the IL-6 response (in terms of
the decrease in absorption intensity) is noticeably different
from the control (Fig. 2d) even at lower IL-6 concentrations
(56.6 μg·mL−1 for 15 nm and 22 μg·mL−1 for 50 nm). It
should be noted that a low concentration of 50 nm aptamer-
AuNP (ca. 0.01 nM) is used in this experiment. A shift in the
wavelength maximum of 4 nm (compared to a 1.5 nm shift for
the buffer control) is again achieved in the experiment shown
in Fig. 2. This time, half the concentration of IL-6 is used
when compared with that used for the 15 nm AuNP core size.
This response is also observed during repeat experiments (n =
2). It is therefore concluded that the 50 nm AuNP core size
yielded an improved assay response in terms of particle ag-
gregation when compared to smaller AuNP. Based on these
results, and those of the previous set of experiments, 50 nm
mixed aptamer-AuNP are used for all subsequent tests.
Experiments are also performed to determine whether
AuNP functionalised with a single aptamer, or a mixture of
both aptamers (in an approximate 1:1 ratio) would improve
aggregation and test response. It is hypothesised that by co-
functionalising the AuNP with both aptamers, this would im-
prove the rate of aggregation by increasing the number of
possible binding arrangements and preventing steric hin-
drance. For the co-functionalised AuNP, a 1:1 ratio of the
two aptamers on the AuNP surface is assumed based on the
equal amount of each aptamer applied during functionalisa-
tion (as detailed in the methods section). Complete character-
isation of the resulting ratio was not performed as part of this
pilot study. The titration of IL-6 was performed as described in
the previous experiments.
Results from an example experiment conducted using 50 nm-
sized AuNP are shown in Fig. 3. Here the results shown are
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expressed as absorption at 540 nm normalised to AuNP concen-
tration, to enable direct comparison with the control aptamer-
AuNP 1 with the mixed aptamer-AuNP in Fig. 3a (the same
units are used in Fig. 3b for consistency). For the single-
aptamer-AuNP (Fig. 3a), the level of aggregation is not readily
distinguishable from the binding control (in which only one of
the two aptamer-AuNP required for aggregation was present).
However, for the mixed-aptamer-AuNP, the IL-6 response is
markedly different from the buffer control (Fig. 3b). The
mixed-aptamer-AuNP therefore yields more aggregation when
compared to the single-aptamer-AuNP, suggesting that a greater
number of binding opportunities do improve the response of the
test. This improved response is also observed during repeat ex-
periments using ca. 50 nm-sized AuNP (n = 2). Similar experi-
ments are performed using ca. 15 nm sized AuNP. The effects of
co-functionalisation on AuNP of this size is less obvious than
with the larger sized AuNP due to the lower degree of aggrega-
tion achieved (as previously discussed). Based on the results
exemplified in Fig. 3, 50 nm mixed-aptamer-AuNP are used
for all subsequent experiments. The investigation of other co-
functionalisation ratios were not explored in this pilot study.
However, in future, these may be considered as a means of
optimising assay sensitivity for biological application.
Aggregation assay results – Analysing IL-6 standard
solutions
The performance of the assay, now comprising of 50 nm
mixed-aptamer-AuNP, is further determined via titrations of
increasing concentrations of IL-6 (in buffer). This time a larger
IL-6 concentration range than previously attempted (to a final
concentration of 109.4 μg·mL−1) is explored. The starting
concentration of the 50 nm mixed-aptamer AuNP (prior to
addition of IL-6) is also increased 5-fold, from ca. 0.01 nM
(as used in previous experiments, e.g. as shown in Fig. 3b), to
ca. 0.05 nM. This change is made with the aim of producing a
visual colour change.
Results from a typical experiment are shown in Fig. 4a, b
and c. The UV-Vis absorption spectrum shows a steady de-
crease in the intensity of the surface plasmon absorption band
Fig. 2 Comparing the effects of AuNP core size on IL-6 induced aggre-
gation: 15 versus 50 nm (single) aptamer-AuNP. UV-Vis absorption spec-
tra showing the decrease in the surface plasmon absorption band intensity
in response to increasing concentrations of IL-6 for the 15 nm aptamer-
AuNP (a) and for the 50 nm aptamer-AuNP (c). Aptamer-AuNP concen-
trations prior to IL-6 addition are an estimated 2.21 nM and 0.01 nM for
the 15 nm and 50 nm aptamer-AuNP, respectively. Changes in the ab-
sorption intensity of 15 nm aptamer-AuNP (b, blue) and 50 nm aptamer-
AuNP (d, blue) at the maximum wavelength with increasing concentra-
tions of IL-6 are compared with those changes observed following addi-
tion of a buffer control (b and d red, respectively). Results shown are from
a single set of experiments, representative of all repeats (n = 2)
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at ca. 540 nm in response to increasing IL-6 (Fig. 4a). A
typical red shift in the absorption wavelength maximum of
7 nm is observed in the test solution in this experiment (com-
pared to a zero nm shift in the control solution). This shift
further confirms the aggregation of the aptamer-AuNP in re-
sponse to IL-6. A comparison between absorption at the λmax
(ca. 540 nm) in response to either IL-6 or an equal volume of
blank buffer is shown in Fig. 4b. There is a clear response to
increasing IL-6 addition which is readily distinguishable from
the dilution effect illustrated by the control sample. The ag-
gregation of the aptamer-AuNP is further demonstrated in Fig.
4c, which shows the colour change in response to 109.4 μg·
mL−1 IL-6 (compared with the control). Characterisation of
the AuNP core, aptamer-functionalised AuNP, and control
versus IL-6 aggregation test samples was also performed by
DLS. The DLS results (Fig. 4d) indicate an original
hydrodynamic diameter of the AuNP of approximately
50 nm, which increases by an estimated 30–40 nm with the
addition of aptamers to the AuNP surface. Results shown in
Fig. 4d are cumulative results from two repeat experiments
(see Table S3 for complete DLS results). In the absence of
IL-6, the control sample (in which equal volumes of buffer
are added instead of IL-6) results in a size estimate comparable
to that of the aptamer-functionalised AuNP, confirming a lack
of aggregation. Conversely, in the presence of IL-6, large
AuNP aggregates estimated at 600 nm in size are formed,
confirming successful aggregation of the aptamer-AuNP in
the presence of the marker of inflammation.
The performance of the aggregation assay is further deter-
mined by another titration of increasing volumes of IL-6 (to a
final concentration of 125 μg·mL−1), but this time in a mixed
protein solution broadly representative of a biological matrix.
Fig. 3 Comparing the effects of aptamer arrangement on IL-6-induced
aggregation of ca. 50 nm AuNP: single aptamer versus mixed aptamer
AuNP functionalisation. All results are expressed as absorption at 540 nm
normalised to AuNP concentration, to correct for the difference in AuNP
concentrations between the control and test in (a). Decreasing absorption
intensity at the λmax (ca. 540 nm) in response to increasing concentrations
of IL-6 for the single-aptamer AuNP: Amax comparison with control (a).
The final concentration of IL-6 in (a) is 45.45 μg·mL−1. The control used
is a binding control, where IL-6 is titrated into a solution of single
aptamer-AuNP (with the complimentary binding aptamer missing, as
shown in the diagram). The response to increasing concentrations of IL-
6 are also shown for the mixed-aptamer-AuNP: Amax comparison with
buffer control (b). The final concentration of IL-6 in (b) is 42.7 μg·mL−1.
Results shown are from a single set of experiments performed on ca.
50 nm AuNP, representative of all repeats (n = 2)
Microchim Acta          (2020) 187:13 Page 7 of 11    13 
The mixed protein solution comprises of human serum albu-
min (HSA) and 34 arbitrary human cytokines and
chemokines, notably including human IL-6 (see Table S2 for
detailed composition of the matrix). Results from a typical
experiment are shown in Fig. 5a, b and c. The UV-Vis absorp-
tion spectrum, showing a steadily decreasing absorption in-
tensity at the λmax (ca. 540 nm) in response to increasing IL-6
(comparable to that obtained using IL-6 in buffer, Fig. 5a). A
red-shift in the λmax of 8.5 nm is again observed in this repre-
sentative experiment (compared to 1.0 ± 0.5 nm for the two
controls). The observed shift confirms aggregation of the
aptamer-AuNP in response to IL-6 without interference from
the sample matrix. A comparison between absorption at the
λmax (ca. 540 nm) in response to either IL-6 or an equal vol-
ume of two control buffers is shown in Fig. 5b. Here the
controls consist of a buffer containing HSA only (‘buffer con-
trol’), and a buffer containing both HSA and the human pro-
tein mix (‘negative control’). The aggregation of the aptamer-
AuNP in response to IL-6 is again clearly distinguishable from
the dilution effect seen with both buffers. By separating the
response of the ‘negative control’ from the ‘buffer’ (dilution
effect) control, this result suggests that no obvious cross-
reactivity with human IL-6 (when present at low concentra-
tions) has occurred during this preliminary test. The aggrega-
tion of the aptamer-AuNP is further demonstrated in Fig. 5c,
which shows the colour change in response to IL-6 versus the
‘negative control’. The ‘buffer control’ also does not yield a
colour change (as shown in Fig. S2). Characterisation of both
controls and the IL-6 aggregation test sample was again per-
formed by DLS. The DLS results (Fig. 5d) show that both
controls result in a size estimate comparable to that of the
aptamer-functionalised AuNP (see Fig. 4d), confirming a lack
of aggregation. Conversely, in the presence of IL-6, large
AuNP aggregates of around 500 nm in size are formed,
confirming successful aggregation of the aptamer-AuNP.
In this pilot study we have demonstrated the applica-
tion of this preliminary assay format for the detection of
IL-6 in the low (1–125) μg·mL−1 range. In biological
samples such as mouse plasma, IL-6 can be present at
concentrations between 1 and 1500 pg·mL−1 (depending
on the health of the animal) [27]. Concentrations of IL-
6 in human serum are in the low pg·mL−1 range in
Fig. 4 Aggregation assay (comprising of 50 nm mixed-aptamer-AuNP)
results for IL-6 standard in buffer. Decreasing absorption intensity at the
λmax (ca. 540 nm) in response to increasing concentrations of IL-6: UV-
Vis absorption spectra (a), and absorption at λmax comparison with buffer
control (b). The visible colour change of the final test solution (containing
109.4 μg·mL−1 IL-6) compared with the control sample containing an
equivalent volume of blank buffer (c). Results shown in a, b and c are
from a single experiment, representative of all repeats (n = 2). Aptamer-
AuNP concentration prior to IL-6 addition is estimated at 0.05 nM.
Characterisation of the cAuNP core, aptamer-AuNP, test control, and
the test solution (containing 109.4 μg·mL−1 IL-6) by DLS (d). The size
estimates shown are based on 10 repeat measurements (n = 2 separate
experiments); error bars denote SD of repeat measurements
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healthy controls and increase significantly in various
disease states. For example, Robak et al. reported serum
IL-6 concentrations of 0.5–16.6 pg·mL−1 in healthy con-
trols and 1.5–234 pg·mL−1 in rheumatoid arthritis pa-
tients [28]. In intensive care unit patients with sepsis,
Damas et al. reported IL-6 serum concentrations of
200–461,850 pg·mL−1 [29]. Full optimisation of the
present assay to achieve a lower limit of detection,
and a comparison with current state-of-the-art point-of-
care assays is necessary, but was beyond the scope of
this small pilot study. There is considerable opportunity
for further development and optimisation to achieve a
lower limit of detection, for example by adapting the
concentration of aptamer-AuNP in the test solution, or
by investigating different co-functionalisation ratios for
improved binding efficacy. With further optimisation, a
test of this nature may be readily applied for the rapid
analysis of relevant biological samples. Here we have
demonstrated the potential of this assay format, with a
view to future clinical application. This will involve
development and complete validation of this promising
assay format with appropriate aptamers targeted to hu-
man inflammatory markers.
Conclusions
A proof-of-concept aptamer-based assay format for detecting
IL-6, a key marker of acute inflammation, has been presented.
The assay is based on the aggregation of AuNP coated in two
complimentary “sandwich-style” aptamers, which each bind
to different sites on the IL-6 peptide. The aggregation of
AuNP in the presence of IL-6 induces a visible colour change
in just 5 min, with a corresponding change in absorption in-
tensity at ca. 540 nm which can be monitored by spectropho-
tometer or plate reader. Size increase upon aggregation can be
also followed by DLS measurements. In this pilot study, key
aspects of the assay format (AuNP size and aptamer arrange-
ment) are investigated to improve the level of aggregation and
sensitivity achieved. The assay is successfully applied to the
detection of murine IL-6 (in the μg·mL−1 range) in buffer, and
in a mixed protein solution broadly representative of a
Fig. 5 Aggregation assay (comprising of 50 nm mixed-aptamer-AuNP)
results for IL-6 standard in a broadly representative sample matrix.
Decreasing absorption intensity at the λmax (ca. 540 nm) in response to
increasing concentrations of IL-6: UV-Vis absorption spectra (a), and
changes in the absorption maxima in comparison with controls (b). The
‘buffer control’ contains HSA only; the ‘negative control’ contains both
HSA and a mixture of human cytokines and chemokines as a represen-
tative sample matrix (as listed in Table S2). The visible colour change of
the final test solution (containing 125 μg·mL−1 IL-6), compared with the
‘negative control’ (c). Results shown in a, b and c are from a single
experiment, representative of all repeats (n = 2). Aptamer-AuNP concen-
tration prior to IL-6 addition is estimated at 0.08 nM. Characterisation of
the controls and the test solution (containing 125 μg·mL−1 IL-6) by DLS
(d). The size estimates are based on 10 repeat measurements (n = 2 sep-
arate experiments); error bars denote SD of repeat measurements
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biological sample matrix. This proof-of-concept study does
not, as yet, possess the sensitivity to detect the low levels of
IL-6 in healthy serum/plasma. More work is needed to im-
prove the sensitivity. During infections and sepsis very high
levels are known to occur in patients (see above). With further
development and optimisation to improve the limit of detec-
tion, this assay format may enable rapid and straightforward
detection of acute inflammation in either a mouse model, or in
mouse-derived cell culture supernatant. This pilot study was
performed as a proof-of-concept demonstration of aptamer-
functionalised AuNP, with a view to developing a similar
assay targeting human inflammatory markers for analysing
patient samples in future. The principle of our assay may, with
further development, lead to a rapid point-of-care test in
patients.
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